The Indonesian Association of Dermatology and Venereology (PERDOSKI) has officially addressed a rapidly growing viral trend on social media regarding a South Korean cosmetic skin booster informally dubbed by the public as the "corpse skin" injection. This controversial aesthetic treatment has sparked widespread debate, curiosity, and apprehension across various digital platforms due to public speculation that the active ingredients are derived directly from human cadavers.
The discussion centers around the utilization of Human Acellular Dermal Matrix (hADM) as the primary raw material for these advanced dermatological products originating from East Asia. While the nomenclature used by internet users is sensational and alarming, medical professionals emphasize the need to look past the colloquial terminology and examine the actual biochemical and regulatory realities of such biomedical innovations. As aesthetic medical tourism and cross-border cosmetic trends continue to influence consumer behavior in Southeast Asia, regulatory bodies like PERDOSKI find themselves at the forefront of evaluating foreign medical technologies that enter the domestic market through unofficial channels or social media hype.
Understanding Human Acellular Dermal Matrix (hADM) in Medical Context
To comprehend the scale of the controversy, it is essential to analyze what Human Acellular Dermal Matrix actually is within the broader spectrum of medical science. hADM is a processed tissue product derived from human skin donor tissue. During the manufacturing process, the cellular components of the dermal tissue—including the cells that trigger immune responses and rejection—are completely removed through specialized decellularization techniques. What remains is a purified structural scaffolding composed primarily of collagen, elastin, and other extracellular matrix proteins.
In legitimate global medical practice, hADM has a long and respected history primarily centered on reconstructive surgery, burn management, and plastic surgery procedures. It has been routinely utilized for complex wound healing, breast reconstruction following mastectomy, periodontal regeneration, and severe soft tissue defect repairs. The matrix acts as a biological scaffold that encourages the patient’s own cells to migrate, proliferate, and vascularize the area, ultimately integrating the donor structure into the host’s living tissue.
However, the recent pivot of hADM technology toward the cosmetic skin booster market—particularly in South Korea, a global epicenter for aesthetic innovations—has blurred the lines between reconstructive tissue engineering and routine outpatient anti-aging treatments. This commercial shift is what triggered international discussions and regulatory scrutiny, as consumers and medical practitioners alike question the ethical, safety, and clinical justifications of utilizing human-derived tissue matrices for superficial skin rejuvenation.
Chronology of the Controversy and Social Media Escalation
The trajectory of this issue follows a typical modern digital phenomenon where specialized medical technologies are pulled out of context by social media influencers and transformed into viral sensations.
Phase One: Emergence in Aesthetic Clinics of Seoul
Over the past several months, high-end aesthetic clinics in South Korea began introducing advanced regenerative skin boosters marketed for their superior collagen-stimulating properties. These products allegedly incorporated hADM components to accelerate skin healing, improve elasticity, and provide profound anti-aging effects compared to traditional hyaluronic acid fillers or vitamin mesotherapy.
Phase Two: Digital Translation and Sensationalism
As beauty enthusiasts from Indonesia and other neighboring countries traveled to South Korea for medical tourism—or encountered promotional content from overseas practitioners—the technical term Human Acellular Dermal Matrix was translated and reinterpreted. Due to the understanding that the raw material originates from human skin donors, internet commentators coined the sensationalized and graphic term "suntik kulit mayat" or "corpse skin injection." The narrative quickly spread across platforms like TikTok, Instagram, and X (formerly Twitter), generating a mixture of fascination and deep ethical unease among prospective consumers.
Phase Three: PERDOSKI Intervention and Official Stance
Prompted by the rising public confusion and the potential health risks associated with unverified cosmetic trends, media outlets sought clarification from Indonesia’s highest authority in dermatology. On Wednesday, September 16, 2026, the Chairperson of the Central Board of PERDOSKI, Dr. dr. Hanny Nilasari, Sp.DVE, Subsp.Ven, FINSDV, FAADV, released an official statement addressing the phenomenon. Her remarks aimed to debunk misconceptions while simultaneously highlighting the absolute lack of transparent clinical data regarding these specific cosmetic formulations.
Expert Clarifications from PERDOSKI Leadership
Addressing the media representatives, Dr. Hanny Nilasari confirmed the biological origin of the core ingredient while simultaneously correcting the misleading public narrative. She clarified that while the material is indeed sourced from human tissue donations, the colloquial terminology used by the public fails to capture the complex medical reality of the substance.
"So, it is indeed made from a tissue matrix derived from a donor. But the donor itself is something we do not know—whether it is a living donor or a deceased donor," Dr. Hanny explained during her interview. "However, the term ‘corpse skin injection’ does not actually describe the true nature of the procedure."
Dr. Hanny further elaborated that the primary hurdle facing Indonesian dermatologists is the absolute absence of transparent scientific literature detailing how these specific cosmetic skin boosters are manufactured. While hADM as a raw material is well-documented in reconstructive surgery textbooks, the proprietary formulas, processing methods, and viral viral-specific strains used by South Korean cosmetic laboratories remain largely undisclosed to the international scientific community.
"So, for the technical aspects, we truly do not understand them yet," she added, emphasizing that the medical community relies on peer-reviewed data rather than marketing claims when evaluating the safety and efficacy of novel treatments.
Regulatory Hurdles and Patient Safety Standards in Indonesia
The introduction of any foreign medical or aesthetic product into the Indonesian market is governed by stringent regulatory frameworks designed to protect public health. The Indonesian Ministry of Health, in coordination with the Indonesian Food and Drug Authority (BPOM) and professional medical associations like PERDOSKI, enforces rigorous evaluation protocols before any therapeutic or cosmetic agent can be legally administered to patients.
Dr. Hanny underscored that the core philosophy governing Indonesian dermatology is patient safety above all commercial trends. Because hADM involves human biological material, the regulatory requirements are exponentially higher than those applied to synthetic or plant-based compounds. These requirements span several critical dimensions:
- Patient Safety and Biocompatibility: Comprehensive clinical trials must demonstrate that the product does not carry risks of localized adverse reactions, granuloma formation, or chronic inflammation when applied via superficial micro-injections for aesthetic purposes.
- Ethical Sourcing and Chain of Custody: Regulatory authorities must verify the absolute traceability of the human tissue donors. International medical ethics strictly prohibit the commercialization or unethical acquisition of human organs and tissues. Clear documentation must prove that tissues were procured with informed consent, adhering to international bioethical standards.
- Pathogen Safety and Sterilization: Any product derived from human tissue carries an inherent, albeit low, risk of transmitting blood-borne pathogens, viral infections, or prion diseases if the viral inactivation and decellularization protocols are flawed. Rigorous scientific validation of the manufacturing process is non-negotiable.
- Legal Compliance and Transparency: Importers and manufacturers must provide complete transparency regarding the chemical composition, cellular debris clearance rates, and structural integrity of the matrix.
"And then, if it is in Indonesia itself, we certainly need patient safety—the safety of patients who have received treatments from us—followed by legality, and transparency of the materials we use," Dr. Hanny stated. "Perhaps if all of those conditions have been met and fulfilled, we can review whether it can be approved for entry into Indonesia."
Broader Implications for the Aesthetic Industry and Medical Tourism
The controversy surrounding the hADM skin boosters highlights a broader vulnerability within the modern globalized beauty industry. As cosmetic procedures become increasingly sophisticated and heavily influenced by social media algorithms, consumers are frequently exposed to cutting-edge biotechnologies long before local regulatory bodies have time to conduct thorough safety evaluations.
South Korea remains a global powerhouse in dermatological research and aesthetic device manufacturing, producing world-class innovations that have revolutionized skincare. However, the commercial pressure to outpace competitors can sometimes lead to the premature marketing of medical-grade technologies—such as tissue-engineered matrices—for everyday aesthetic maintenance in commercial beauty salons or non-reconstructive clinics.
Medical experts warn that applying reconstructive-grade biological scaffolds for routine skin glowing or anti-aging purposes represents a significant paradigm shift. Reconstructive materials are typically designed to repair structural defects, close massive wounds, or rebuild lost anatomical volumes. Using them as superficial mesotherapy boosters raises valid questions regarding cost-benefit ratios, long-term tissue behavior, and the appropriateness of utilizing scarce human donor tissues for cosmetic enhancements rather than life-altering reconstructive surgeries.
Furthermore, the rise of cross-border medical tourism means that adventurous consumers often travel abroad to receive treatments that lack approval in their home countries. When these individuals return, local dermatologists are occasionally left to manage delayed complications, adverse inflammatory responses, or infections caused by products whose biochemical properties and composition remain unknown to domestic medical practitioners.
Conclusion and Future Outlook
The official stance articulated by PERDOSKI serves as both a cautionary advisory to the public and a reminder of the rigorous scientific standards required in modern medicine. While the viral "corpse skin" narrative is largely a sensationalized exaggeration born of internet speculation, it successfully draws attention to the complex ethical, regulatory, and safety questions surrounding human tissue-derived cosmetics.
Until manufacturers of hADM-based skin boosters provide comprehensive, transparent, and peer-reviewed scientific data regarding their sourcing, processing safety, and clinical efficacy for aesthetic indications, Indonesian regulatory agencies and professional associations will maintain a cautious stance. Patients and consumers are strongly advised to exercise high levels of skepticism, consult board-certified dermatologists, and prioritize verified, legal, and scientifically validated treatments over unverified international beauty trends promoted on social media.
